Share Prices & Company Research

Market News

22 May 2020 | 16:03

Eco Animal Health gets positive opinion from EMA on Aivlosin use

(Sharecast News) - Eco Animal Health Group announced on Friday that it has received a positive opinion from the European Medicines Agency (EMA) for the use of 'Aivlosin' 625 mg/g water soluble granules for the treatment and metaphylaxis of mycoplasma hyopneumoniae in pigs. The AIM-traded firm explained that mycoplasma hyopneumoniae is "the most common" primary pathogen in pig respiratory disease, and is a "key instigator" of secondary bacterial and viral pathogens.

It said its patented antimicrobial, Aivlosin, is used under veterinary prescription for the treatment of a variety of "economically important" respiratory and enteric diseases in poultry and pigs.

The European Commission was expected to issue a marketing authorisation within two months of the publication of a positive opinion, the board said.

"Aivlosin offers a safe and highly effective medication for Mycoplasma infections," said chief executive officer Marc Loomes.

"This positive opinion is significant, not only in the European Union, which has 15% of the world's pigs, but for other large international swine markets as this indication is rolled out.

"Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin's approved usage continues to expand across multiple treatment areas and markets."

At 1548 BST, shares in Eco Animal Health Group were up 5.32% at 208p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 5th June 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.